Prevention of macrovascular complications in patients with type 2 diabetes mellitus: Review of cardiovascular safety and efficacy of newer diabetes medications.

Even with these limitations and a quarter of the study population without history of CV disease, treatment with exenatide almost reached statistical significance for primary endpoint MACE, and it’s encouraging that direction of CV outcomes was consistent with beneficial effects seen in previous trials.

also in 378 other papers

Once weekly exenatide, however, decreased MACE by 9% and all-cause mortality risk by 14% after 3.2 years of treatment but just failed to reach statistical significance.

also in 203 other papers